Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Effect of Pregnancy in Women with a History of Primary Immune Thrombocytopenia Considered As Cured

Thibault Comont, Guillaume Moulis, MD PhD, Karen Delavigne, MD, Pierre Cougoul, MD, Olivier Parant, MD PhD, Beatrice Guyard Boileau, MD, Christian Récher, MDPhD, Daniel Adoue, MD PhD, Odile Beyne Rauzy, MD PhD

Blood (2016) 128 (22): 2552.

https://doi.org/10.1182/blood.V128.22.2552.2552

Published: 2016

Journal Articles

The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations

Helena Boutzen, PharmD PhD, Estelle Saland, Mathilde Cathebras, Clément Larrue, PhD, Thomas Farge, Nizar Serhan, PhD, Fabienne De Toni, PhD, Marion David, PhD, Lara Gales, Florence Castelli, Christophe Junot, PhD, Eric Delabesse, PharmD PhD, Demas Veronique, PharmD PhD, Jean-Charles Portais, PhD, Ouathek Ouerfelli, PhD, Yang Guangli, PhD, Francois Vergez, VD PhD, Christian Recher, MDPhD, Jean-Emmanuel Sarry, PhD

Blood (2015) 126 (23): 2542.

https://doi.org/10.1182/blood.V126.23.2542.2542

Published: 2015

Journal Articles

Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650)

Yves Bertrand, MDPhD, Hervé Dombret, Bruno Quesnel, MD PhD, Jean-Louis Stephan, MD, Claudine Schmitt, MD, Severine Lissandre, MD, Maryline Poiree, MD, Christian Recher, MDPhD, Emmanuel Plouvier, MD, Cécile Dumesnil de Maricourt, MD, David Salako, MSc, Yann Godfrin, PhD, Iman El Hariry, MDPhD

Blood (2015) 126 (23): 4877.

https://doi.org/10.1182/blood.V126.23.4877.4877

Published: 2015

Journal Articles

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Blood (2015) 126 (23): 3736.

https://doi.org/10.1182/blood.V126.23.3736.3736

Published: 2015

Journal Articles

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Blood (2015) 126 (23): 451.

https://doi.org/10.1182/blood.V126.23.451.451

Published: 2015

Journal Articles

Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

Blood (2015) 126 (23): 3787.

https://doi.org/10.1182/blood.V126.23.3787.3787

Published: 2015

Journal Articles

In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells

Nesrine Aroua, PhD, Jean-Emmanuel Sarry, PhD, Fabienne De Toni, PhD, Robin Carson, MD BA, Francois Vergez, VD PhD, Estelle Saland, Mayumi Sugita, MD, Martin Carroll, MD, Christian Recher, MDPhD, Gwenn Danet, PhD

Blood (2015) 126 (23): 4269.

https://doi.org/10.1182/blood.V126.23.4269.4269

Published: 2015

Journal Articles

Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML

Francois Vergez, DVM, PhD, Sarah Bertoli, MD PhD, Marina Bousquet, PhD, Marie-Laure Nicolau-Travers, Michael Peres, PharmD, Estelle Saland, Françoise Huguet, MD, Isabelle Luquet, MD, Veronique Mansat-de Mas, PharmD, PhD, Cecile Demur, MD, Eric Delabesse, MD PhD, Gwenn Danet-Desnoyers, PhD, Jean-Emmanuel Sarry, PhD, Christian Récher, MDPhD

Blood (2015) 126 (23): 90.

https://doi.org/10.1182/blood.V126.23.90.90

Published: 2015

Journal Articles

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

Lionel Ades, MD PhD, Christian Récher, MDPhD, Julie Lejeune, Aspasia Stamatoullas, MD, Marie Sebert, MD, Jacques Delaunay, MD, Benedicte Samey, Krimo Bouabdallah, MD, Thorsten Braun, MD PhD, Norbert Vey, Sophie Park, MD PhD, Benoit de Renzis, Sylvie Chevret, Pierre Fenaux, MD PhD

Blood (2015) 126 (23): 2892.

https://doi.org/10.1182/blood.V126.23.2892.2892

Published: 2015

Journal Articles

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Alessandro M. Vannucchi, Ruben A. Mesa, Francisco Cervantes, Ritam Prasad, Janos Jakucs, Anna Elinder, Christian Recher, MDPhD, Peter A. te Boekhorst, Steven Knapper, Tim Somervaille, James P. Dean, Tanya Granston, Adam Mead, Claire N. Harrison

Blood (2015) 126 (23): 58.

https://doi.org/10.1182/blood.V126.23.58.58

Published: 2015

Journal Articles

Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia

Christian Recher, MDPhD, Marion David, PhD, Philippe de Medina, PhD, Cécile Bize, PhD, Nizar Serhan, PhD, Michael R Paillasse, PhD, Estelle Saland, Emmanuel Noguer, Julia Cherier, PhD, Cécile Demur, MDPhD, Clément Larrue, Fabienne de Toni, PhD, François Vergez, VMD-PhD, Jean-emmanuel Sarry, PhD, Sandrine Silvente-Poirot, PhD, Marc Poirot, PhD

Blood (2014) 124 (21): 3767.

https://doi.org/10.1182/blood.V124.21.3767.3767

Published: 2014

Journal Articles

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Blood (2014) 124 (21): 621.

https://doi.org/10.1182/blood.V124.21.621.621

Published: 2014

Journal Articles

Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM)

Lydia Roy, MD, Jean Christophe Ianotto, MD, Joelle Guilhot, PhD, Christian Récher, MDPhD, Laurence Legros, MD PhD, Dana Ranta, MD, Emmanuel Raffoux, MD, Pascale Cony Makhoul, Emmanuel Gyan, MD PhD, Benoit de Renzis, MD, Françoise Boyer, MD, Thierry Muron, MD, Franck Emmanuel Nicolini, MD PhD, Kamel Laribi, MD, Jean-Jacques Kiladjian, MD PhD, Stephane Giraudier, MD PhD

Blood (2014) 124 (21): 1845.

https://doi.org/10.1182/blood.V124.21.1845.1845

Published: 2014

Journal Articles

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

Hervé Dombret, MD PhD, Claude Preudhomme, MD PhD, Céline Berthon, MD, Emmanuel Raffoux, MD, Xavier Thomas, MD PhD, Norbert Vey, MDPhD, Carlos Gomez-Roca, MD, Mark Ethell, MD, Karen Yee, MD, Fabrice Bourdel, MSc, Patrice Herait, MD PhD, Mauricette Michallet, MD PhD, Christian Recher, MDPhD, Christophe Roumier, Bruno Quesnel, MD

Blood (2014) 124 (21): 117.

https://doi.org/10.1182/blood.V124.21.117.117

Published: 2014

Journal Articles

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

Blood (2014) 124 (21): 10.

https://doi.org/10.1182/blood.V124.21.10.10

Published: 2014

Journal Articles

A Novel Path for ATRA Differentiation Therapy in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations

Jean-Emmanuel Sarry, PhD, Helena Boutzen, PharmD. PhD, Christian Récher, MDPhD

Blood (2014) 124 (21): 3727.

https://doi.org/10.1182/blood.V124.21.3727.3727

Published: 2014

NARROW

Effect of Pregnancy in Women with a History of Primary Immune Thrombocytopenia Considered As Cured

The Combination of ATRA and Dasatinib for Differentiation Therapy in Acute Myeloid Leukemias with IDH Mutations

Expanded Access Program of Graspa for Treatment of Patients with Acute Lymphoblastic Leukemia Unable to Receive Other Form of L-Asparaginase - a Status Update (NCT02197650)

Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

Is Arsenic Trioxide (ATO) Required in the Treatment of Standard Risk Newly Diagnosed APL? Analysis of a Randomized Trial (APL 2006) By the French Belgian Swiss APL Group

Safety and Long-Term Efficacy of Maintenance Therapy with Alternating Azacytidine (AZA) and Lenalidomide (Len) Cycles in Elderly (≥ 60) Fit Patients (Pts) with Poor Prognosis AML in First Complete Remission (CR) After LIA Induction. A Phase II Multicentric GOELAMS Trial

In Vivo Response to Cytarabine Chemotherapy Uncovers the Role of the Oxidative and Energetic Metabolism in the Chemoresistance of Human Primary AML Stem Cells

Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML

A Phase I-II Study of the Efficacy and Safety of Lenalidomide (LEN) Combined to Azacitidine (AZA) in Higher Risk MDS and AML with Del 5q - a Study By the Groupe Francophone Des Myelodysplasies (GFM)

Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial

Dendrogenin_A : A Natural Liver X Receptor Modulator for the Treatment of Acute Myeloid Leukemia

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM)

A Phase 1 Study of the BET-Bromodomain Inhibitor OTX015 in Patients with Advanced Acute Leukemia

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

A Novel Path for ATRA Differentiation Therapy in Acute Myeloid Leukemia with Isocitrate Dehydrogenase Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only